The price of abrocitinib can vary depending on factors such as dosage, insurance coverage, and pharmacy. Without insurance, a 30-day supply of 100mg abrocitinib can cost around $6,500. Lower doses may be less expensive [1].
How can I find abrocitinib discounts or patient assistance programs?
Patients may be eligible for savings cards or patient assistance programs. For example, Pfizer, the manufacturer of abrocitinib, offers a co-pay savings card that can reduce out-of-pocket costs for eligible commercially insured patients [1]. Specific eligibility criteria and program details are available from the manufacturer.
When does abrocitinib's patent expire?
The patent landscape for abrocitinib is complex and involves multiple patents covering different aspects of the drug, including its composition of matter and methods of use. According to DrugPatentWatch.com, the earliest projected patent expiry date for abrocitinib is in 2034 [2]. However, patent challenges and additional patent filings can affect these timelines [2].
What is abrocitinib used for?
Abrocitinib is a Janus kinase 1 (JAK1) inhibitor approved for the treatment of moderate to severe atopic dermatitis in adults and adolescents whose disease is not adequately controlled with other medications [1].
How does abrocitinib work?
Abrocitinib works by selectively inhibiting JAK1. This enzyme plays a role in the signaling pathways of several cytokines involved in inflammation and immune responses, including those that contribute to atopic dermatitis [1]. By blocking JAK1, abrocitinib helps to reduce inflammation and the associated symptoms of the condition.
What are the potential side effects of abrocitinib?
Common side effects of abrocitinib can include upper respiratory tract infections, acne, and increased levels of creatine phosphokinase in the blood [1]. More serious side effects can occur, and it is important for patients to discuss potential risks and benefits with their healthcare provider.
Can biosimilars be developed for abrocitinib?
The development of biosimilars for abrocitinib would depend on the expiry of relevant patents and regulatory approvals. Given that abrocitinib is a small molecule drug, the concept of "biosimilar" does not directly apply in the same way it does for biologic drugs. However, generic versions could potentially be developed after patent expiry [2].
Who manufactures abrocitinib?
Abrocitinib is manufactured by Pfizer [1].
What is the dosage of abrocitinib?
Abrocitinib is available in 200 mg, 100 mg, and 50 mg strengths [1]. The recommended starting dose for adults with atopic dermatitis is typically 200 mg once daily, which may be reduced based on patient response and tolerability [1].
Sources:
[1] https://www.webmd.com/drugs/2/234107/abrocitinib-oral
[2] https://drugpatentwatch.com/